Daniel G Bichet Selected Research

migalastat

12/2021	Corrigendum to "Long-term follow-up of renal function in patients treated with migalastat for Fabry disease" [Bichet et al., MGM Reports; 28 (2021) 100786].
9/2021	Long-term follow-up of renal function in patients treated with migalastat for Fabry disease.
1/2021	Assessment of plasma lyso-Gb3 for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease.
1/2021	Correction: Assessment of plasma lyso-Gb3 for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease.
9/2019	The migalastat GLP-HEK assay is the gold standard for determining amenability in patients with Fabry disease.
1/2019	Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study.
1/2019	Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study.
1/2018	Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial.
1/2017	The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat.
1/2017	Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Daniel G Bichet Research Topics

Disease

26	Fabry Disease (Fabry's Disease) 12/2021 - 01/2007
26	Nephrogenic Diabetes Insipidus 08/2020 - 06/2000
8	Autosomal Dominant Polycystic Kidney (ADPKD) 09/2021 - 06/2012
5	Diabetes Insipidus 01/2022 - 07/2005
5	Hyponatremia 10/2014 - 04/2010
4	Neurogenic Diabetes Insipidus (Central Diabetes Insipidus) 10/2017 - 10/2005
3	Disease Progression 12/2021 - 10/2015
3	Chronic Renal Insufficiency 09/2021 - 12/2014
3	Inborn Genetic Diseases (Disease, Hereditary) 01/2016 - 10/2004
3	Dehydration (Water Stress) 01/2016 - 11/2012
3	Polyuria 12/2014 - 04/2010
3	Polycystic Kidney Diseases (Polycystic Kidney Disease) 11/2012 - 07/2011
2	Rare Diseases (Rare Disease) 08/2020 - 06/2000
2	Cysts 01/2019 - 02/2014
2	Diarrhea 01/2019 - 01/2018
2	Diabetes Mellitus 10/2017 - 12/2014
2	Bartter Syndrome (Syndrome, Bartter) 04/2017 - 01/2009
2	Nephrogenic Syndrome of Inappropriate Antidiuresis 10/2012 - 04/2012
2	Hypoxia (Hypoxemia) 01/2012 - 08/2006
2	Cystic Fibrosis (Mucoviscidosis) 07/2010 - 05/2008
1	Pain (Aches) 01/2021
1	X-Linked Genetic Diseases 01/2020
1	Pre-Eclampsia (Preeclampsia) 08/2019
1	Polyhydramnios 04/2017
1	Hyperglycemia 01/2017
1	Cardiomyopathies (Cardiomyopathy) 01/2017
1	Type 2 Diabetes Mellitus (MODY) 05/2015
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 05/2015
1	Fatty Liver 05/2015
1	Glucose Intolerance 05/2015
1	Glycosuria 12/2014
1	Chronic Disease (Chronic Diseases) 12/2014
1	Obesity 01/2014
1	Hemorrhage 01/2014
1	Asthma (Bronchial Asthma) 01/2014
1	Idiopathic Hypogonadotropic Hypogonadism 01/2014
1	type 1 familial Hypocalciuric hypercalcemia 01/2014
1	Seizures (Absence Seizure) 04/2012

Drug/Important Bio-Agent (IBA)

30	Vasopressins (Vasopressin)IBA 01/2022 - 04/2002
17	Vasopressin Receptors (Arginine Vasopressin Receptor)IBA 08/2020 - 06/2000
12	migalastatIBA 12/2021 - 01/2015
11	Aquaporin 2IBA 06/2012 - 04/2002
10	Arginine Vasopressin (Argipressin)IBA 08/2020 - 04/2002
8	GalactosidasesIBA 08/2020 - 12/2010
7	Proteins (Proteins, Gene)FDA Link 08/2019 - 10/2004
7	SodiumIBA 10/2014 - 07/2005
6	Aquaporins (Water Channels)IBA 08/2020 - 06/2002
5	Deamino Arginine Vasopressin (Desmopressin)FDA LinkGeneric 01/2022 - 07/2005
5	Tolvaptan FDA Link 09/2021 - 04/2010
5	Biomarkers (Surrogate Marker)IBA 08/2020 - 12/2010
4	agalsidase beta FDA Link 01/2019 - 01/2007
4	globotriaosylceramide (globotriosylceramide)IBA 01/2019 - 03/2008
3	agalsidase alfaIBA 12/2021 - 01/2015
3	globotriaosyl lysosphingolipidIBA 01/2021 - 12/2010
3	EnzymesIBA 08/2020 - 03/2008
3	ElectrolytesIBA 10/2014 - 12/2012
2	alpha-Galactosidase (Beano)IBA 12/2021 - 03/2008
2	Sodium Chloride FDA LinkGeneric 04/2017 - 01/2009
2	GlycosphingolipidsIBA 01/2016 - 12/2010
2	Glucose (Dextrose)FDA LinkGeneric 05/2015 - 12/2014
2	Hormones (Hormone)IBA 12/2014 - 04/2012
2	lixivaptanIBA 12/2012 - 12/2012
2	IonsIBA 06/2012 - 05/2006
2	Antidiuretic Hormone Receptor AntagonistsIBA 04/2010 - 08/2004
1	podocalyxinIBA 08/2019
1	NPHS2 proteinIBA 08/2019
1	Adenosine Monophosphate (AMP)IBA 01/2019
1	Dietary SodiumIBA 01/2018
1	AcidsIBA 01/2018
1	ProinsulinIBA 10/2017
1	proAVP hormoneIBA 10/2017
1	Membrane Proteins (Integral Membrane Proteins)IBA 04/2017
1	SphingolipidsIBA 01/2017
1	Phenobarbital (Luminal)FDA Link 01/2016
1	Insulin (Novolin)FDA Link 05/2015
1	CholesterolIBA 05/2015
1	Triglycerides (Triacylglycerol)IBA 05/2015
1	Pyruvic Acid (Pyruvate)IBA 05/2015
1	Nonsense Codon (Nonsense Mutation)IBA 02/2014
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2014
1	Rhodopsin (Visual Purple)IBA 01/2014
1	Parathyroid Hormone (Parathormone)IBA 01/2014
1	NeuropeptidesIBA 01/2014
1	Thyrotropin (Thyroid-Stimulating Hormone)FDA Link 01/2014
1	Endothelins (Endothelin)IBA 01/2014
1	Gonadotropin-Releasing Hormone (GnRH)FDA Link 01/2014
1	Luteinizing Hormone (Lutropin)FDA LinkGeneric 01/2014
1	Follicle Stimulating Hormone (Follitropin)FDA Link 01/2014
1	GTP-Binding Proteins (G-Protein)IBA 01/2014
1	Melanocortin Receptors (Melanocortin Receptor)IBA 01/2014
1	Calcium-Sensing ReceptorsIBA 01/2014
1	MelanocortinsIBA 01/2014
1	Adrenocorticotropic Hormone (ACTH)FDA Link 01/2014
1	Urea (Carbamide)FDA LinkGeneric 06/2012
1	Cystinyl AminopeptidaseIBA 01/2012
1	Blood Coagulation Factors (Coagulation Factor)IBA 07/2011

Therapy/Procedure

8	Therapeutics 01/2022 - 01/2007
8	Enzyme Replacement Therapy 12/2021 - 01/2015
1	Bioreactors (Bioreactor) 12/2021
1	Time-to-Treatment 01/2016